MECHELEN, BELGIUM--(Marketwire - January 16, 2013) - Galapagos NV (Euronext: GLPG) announced
today that it has identified a second pre-clinical compound in its alliance
Janssen Pharmaceutica NV. This achievement triggered a milestone payment
million to Galapagos.
In 2007, Galapagos announced an alliance agreement with Janssen
providing it with option rights to acquire worldwide, commercial
certain Galapagos internal programs. The milestone announced today
the delivery of a second pre-clinical candidate developed by Galapagos.
"We are very pleased to announce the delivery of a second candidate drug
alliance with Janssen," said Onno van de Stolpe, CEO of Galapagos.
is progressing multiple programs successfully across different
delivering promising candidate drugs."
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical
biotechnology company specialized in the discovery and development of
molecule and antibody therapies with a novel mode-of-action. The
progressing four clinical, six pre-clinical, and 30 discovery programs in
fibrosis, inflammation, antibiotics, metabolic disease, and other
Its lead program is GLPG0634, an orally-available, selective inhibitor of
for the treatment of rheumatoid arthritis and potentially other
diseases. In two four-week Phase 2 studies, GLPG0634 showed improvement
signs and symptoms of rheumatoid arthritis and a unique safety profile.
month Phase 2b study is expected to start Q2 2013 with top line data
Q4 2014. AbbVie and Galapagos signed a worldwide license agreement
AbbVie will be responsible for further development and commercialization
Phase 2b. Galapagos is also progressing two other clinical development
with clinical readouts expected in 2013: GLPG0187, a novel integrin
antagonist in development for metastasis, is in a Phase 1b patient
GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically
treatment of IBD. This program is in a second Phase 1 study and will
Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus,
Fidelta, has over 800 employees and operates facilities in five countries,
global headquarters in Mechelen, Belgium. Further information about the
and its drug development programs can be found online at: www.glpg.com
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE